Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tevogen Bio Holdings Inc. - Common Stock (NQ: TVGN ) 0.3170 +0.0121 (+3.97%) Streaming Delayed Price Updated: 10:44 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 45,542 Open 0.3190 Bid (Size) 0.3101 (5) Ask (Size) 0.3286 (1) Prev. Close 0.3049 Today's Range 0.3157 - 0.3299 52wk Range 0.3016 - 21.09 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation September 24, 2024 From Tevogen Bio Inc Via GlobeNewswire Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket September 10, 2024 Via Benzinga Performance YTD -96.83% -96.83% 1 Month -32.70% -32.70% 3 Month -55.41% -55.41% 6 Month -89.25% -89.25% 1 Year -96.83% -96.83% More News Read More Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket August 26, 2024 Via Benzinga Tevogen Bio Secures $6 Million Series C Preferred Stock Investment August 22, 2024 From Tevogen Bio Inc Via GlobeNewswire CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health August 14, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities August 09, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback July 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian July 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility July 08, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities June 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances June 25, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference June 18, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Set to Join Russell 3000® Index June 12, 2024 From Tevogen Bio Inc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 12, 2024 Via Benzinga Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts June 11, 2024 From Tevogen Bio Inc Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session June 07, 2024 Via Benzinga CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event June 07, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session June 06, 2024 Via Benzinga Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024 May 30, 2024 Via InvestorPlace Tevogen Bio Reports First Quarter 2024 Financial Results May 29, 2024 From Tevogen Bio Inc Via GlobeNewswire Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket May 21, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
